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Synovial sarcoma accounts for about 10% of adult soft tissue
sarcomas, with 80–90% located in the limbs. Gastrointestinal
tract involvement is rare. Synovial sarcoma has a propensity
for local recurrence and lung metastases, which can be
delayed beyond 5 years. The t(X;18) translocation resulting in
the expression of a SYT–SSX fusion protein is commonly
seen. Demonstration of this type of genetic rearrangement by
ﬂuorescenceinsituhybridizationorPCRisfundamentaltothe
diagnosis of synovial sarcoma in unusual sites. Owing to the
rarity of this tumor in the gastrointestinal tract, the appropriate
method and extent of surgical resection is uncertain.
We encountered a 44-year-old woman who underwent a
gastroscopy for the diagnosis of melaena and epigastric pain.
A 2-cm ulcerated polypoidal lesion on the proximal lesser
curvewasfound,andacomputerizedtomographicscanofthe
abdomen and pelvis conﬁrmed an ulcerated polypoidal mass
in the proximal stomach with a maximum diameter of 4.7cm.
A computerized tomographic abdomen and pelvis done 14
monthspriorwasreportedasnormal, however,inretrospecta
2.2-cm mass was noticeable. A laparoscopic wedge excision
of the lesion was undertaken for presumed gastrointestinal
stromal tumor (GIST). Histology showed a malignant spindle
cell tumor arising in the stomach wall involving the muscularis
propria, with extension into the mucosa and subserosal
connectivetissue,butnotbreaching theserosalmesothelium.
The tumor had an extensive inﬁltrative nature, extending
beyond the macroscopically deﬁned tumor. The tumor was
positive for CD99 and focal keratin (AE1/AE3 and CK7) but
therewasnoKITimmunoreactivitydetected.Re-arrangement
in the SYT region was detected by ﬂuorescence in situ
hybridization, consistent with monophasic synovial sarcoma.
Subsequently a wider excision of the tumor site was
performed via an upper midline laparotomy. The patient
remains well 40 months after the second operation. Upper
endoscopy at 24 months, and computerized tomographic
scan of the chest and abdomen 5 years after surgery show no
evidence of recurrence.
In all, 10–20% of synovial sarcomas involve the head,
neck, chest, or abdomen. Most abdominal tumors involve
the body wall or retroperitoneum. Visceral involvement is
rare but has been described in the gastrointestinal tract as
well as the head and neck, mediastinum, heart, kidney,
prostate, and vulva. Most case reports for gastrointestinal
synovial sarcomas focus on pathological aspects. Follow-up
wasusuallylimited,andlittledetailwasgivenregardingnature
of the surgery or patterns of recurrence. This makes
conclusions about the most appropriate form of treatment
difﬁcult. The behavior of synovial sarcomas of other sites may
be relevant.
The overall survival for patients with localized primary
synovial sarcoma is 61% at 5 years and 42% at 10 years in
large series of predominantly limb tumors.
1 Late presentation
of local and distant metastases is well recognized. Tumor size
has consistently been shown to be an important prognostic
feature with tumors o5cm having improved survival. Patient
age, tumor location, grade, mitotic activity, bone, or neuro-
vascular invasion and SYT–SSX fusion type have variably
beenshowntobeindependentpredictorsofsurvival.Atotalof
12 synovial sarcomas of the stomach have been reported, 10
of which had follow-up of varying length.
2,3 One 16cm tumor
had multiple liver metastases at presentation. Recurrence
was reported in one of the ﬁve cases o4cm in size, with this
tumor having a poorly differentiated component. Recurrence
was seen in three of four tumors 4cm or greater in size.
Synovial sarcoma has a propensity to local recurrence
particularly when excised without a margin of macroscopically
normal tissue. In a series of synovial sarcomas assessed at
the Royal Marsden Hospital Sarcoma Unit, a local recurrence
rate of 74% was seen following marginal excision or
enucleation without description of margins, 55% following
excision with microscopically involved margins, and 18%
following excision with microscopic margins free of tumor.
4
IntheseriesdescribedbyBerghetal.
5,themajorityofpatients
who developed local recurrence had marginal or intralesional
excisions in hospitals, which were not musculoskeletal tumor
centers.
The most common site of metastases reported in series
of synovial sarcomas from all sites is the lung. Previous
retrospective studies have suggested that synovial sarcomas
have a higher rate of nodal involvement than other sarcomas.
However, large prospective databases report lymph node
metastases in 0–3.3%. Interestingly in Deshmukh et al.
1
series, the only patients with metastastatic disease who
survived for 410 years, were the two with nodal metastases.
In Makhlouf et al.
2 series of gastric synovial sarcomas, ﬁve
patients were treated by segmental or wedge resection and
ﬁve had partial gastrectomy. About four of eight patients with
follow-up developed recurrence (one wedge resection and
three partial gastrectomies). In two cases this was peritoneal
disease and in the other cases the pattern of recurrence is not
documented. Billings et al.
3 describes two cases of synovial
sarcoma involving the stomach both of which were treated by
gastrectomy. One patient had multiple liver metastases at
presentation and the other patient was disease free after
21 months of follow-up.
We are aware of the reports of synovial sarcoma of
the esophagus (10 cases), duodenum (3 cases), 4 small
bowel (2 cases), small bowel mesentery, ascending colonic
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node metastases are not described in any of these reports.
There is also limited information about patterns of recurrence
as most case reports do not have follow-up. A case report of a
5-cmsynovialsarcomaofthedistalduodenumdescribeslocal
recurrence 8 months after resection with clear margins and
negative nodes.
6 Eriksen et al.
7 described a 4-cm synovial
sarcoma of the ileum had an initial resection of 8cm of small
bowel. A subsequent resection of 45cm of small bowel with
resection to the root of the mesentery was performed. A 1-cm
deposit of synovial sarcoma was identiﬁed in the mesentery
adjacent to the previous anastomotic site but no tumor was
found in 31 lymph nodes. There was no recurrence at 24
months. In another case report, intra-abdominal hemorrhage
was found at the time of resection of a 10-cm tumor of the
gastrocolic ligament. This patient had resection of peritoneal
and wound recurrences on four occasions but was alive 6
years after diagnosis.
8 A 7-cm intraluminal synovial sarcoma
of the proximal esophagus was treated by local excision via a
right cervical oesophagotomy. After 10 months a recurrence
developed in the right sternocleidomastoid muscle and
subcutaneous tissue. Excision of the recurrence with right
radical neck dissection found no tumor in the 39 lymph nodes
examined.
9
It is important to distinguish synovial sarcomas from
GIST. The large majority of GIST are diagnosed on the
basis of c-KIT expression. Multiple studies have found
synovial sarcomas are c-KIT negative on immunohisto-
chemical examination. There should be an index of
suspicion for synovial sarcomas in lesions that are weak
or negative for c-KIT and the diagnostic X;18 translocation
should be sought. Gastrointestinal synovial sarcomas may
previously have been diagnosed as leimyosarcoma or
GIST. Increased awareness of the condition and testing
for SYT–SSX gene fusion is likely to lead to increased
numbers of reported cases.
There are no prospective trials of chemotherapy in treat-
ment of synovial sarcoma. The objective response, including
complete response, has been seen with anthracycline–
ifosfamide chemotherapy.
4 This combination was associated
with improved early disease-speciﬁc survival in a multivariate
analysis.
9,10 Randomized trials have shown a reduction in
local recurrence of high-grade limb sarcomas treated with
adjuvant radiotherapy. However, radiation of abdominal
sarcomas is limited by tissue toxicity. The only reports of
radiation of gastrointestinal synovial sarcoma are for tumors
of the cervical esophagus.
Owing to the rarity of gastrointestinal synovial sarcomas
it is difﬁcult to make recommendations regarding optimal
treatment. Our case and the review of the literature support
surgicalresectionasacurativetreatment,bearinginmindthat
late recurrence is well documented for synovial sarcoma.
Gastric synovial sarcomas should have a wider margin of
excision than would be accepted for a GIST, due to the
propensity for local recurrence. However, nodal spread is
uncommon in synovial sarcoma with only peritoneal recur-
rence described in gastric tumors. Therefore, function
preserving local excision is probably preferable to formal
gastrectomy with node dissection where possible.
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